Get the Stockscreener App
33.23
10.77%
3.23
IRulya Therapeutics Inc. Common Stock stock is traded at $33.23, with a volume of 8,851.
It is up +10.77% in the last 24 hours and up +0.00% over the past month.
See More
Previous Close:
$30.00
Open:
$28.9906
24h Volume:
8,851
Relative Volume:
0.22
Market Cap:
$33.80M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$25.13
$33.71
52-Week Range:
$25.13
$33.71
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Company Profile
Name
IRulya Therapeutics Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare IRLA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRLA
IRulya Therapeutics Inc. Common Stock
|
33.23 | 33.80M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-26 | Initiated | Raymond James | Outperform |
| Sep-24-26 | Initiated | Rodman & Renshaw | Buy |
| Sep-22-26 | Upgrade | Citizens | Mkt Perform → Mkt Outperform |
| Aug-20-26 | Initiated | Craig Hallum | Buy |
| Jul-29-26 | Initiated | Oppenheimer | Outperform |
| Jun-24-26 | Initiated | Leerink Partners | Outperform |
| Jun-23-26 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-30-26 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Aug-05-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-24-25 | Initiated | Oppenheimer | Outperform |
View All
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Latest News
Quince Therapeutics relaunched as IRulya: Raymond James targeted QNCX stock at USD 72 - ad-hoc-news.de
IRulya Therapeutics Inc. (IRLA) Company Information - Simply Wall Street
IRulya Therapeutics (Nasdaq:IRLA)Stock Analysis - Simply Wall Street
Diluted net income available to common stockholders of IRulya Therapeutics Inc. – NASDAQ:IRLA - TradingView
Quince relaunches as IRulya, going all in on lung disease after Hail Mary merger - Fierce Pharma
Quince Therapeutics rebrands as IRulya, names new CEO - Investing.com
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease - GlobeNewswire
A $116 million cash balance on June 30, 2026, is expected to fund IRulya's operations through 2028. - Stock Titan
IRulya Therapeutics Inc. Common Stock Stock (IRLA) Financials Data
There is no financial data for IRulya Therapeutics Inc. Common Stock (IRLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):